Abstract
Pancreatic cancer remains a vexing treatment challenge, with a cure rate that remains just 7%. Two effective regimens-gemcitabine/nab-paclitaxel and FOLFIRINOX-have improved outcomes and are being used earlier in the disease. However, meaningful differences in outcomes may not be realized without novel strategies. Targeting of the immune system is an active area of research.
Cite
CITATION STYLE
APA
Tempero, M. A. (2015). Multidisciplinary management of pancreatic cancer. In JNCCN Journal of the National Comprehensive Cancer Network (Vol. 13, pp. 700–702). Harborside Press. https://doi.org/10.6004/jnccn.2015.0208
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free